European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅 ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

欧盟反垄断当局将于2023年12月6日前就诺和控股(Novo Holdings)拟议收购Catalent一事做出决定。作为诺和诺德公司(Novo Nordisk)的控股股东，诺和控股于10月31日寻求欧盟批准该交易。 Catalent是一家在纽约证券交易所上市的合同药品制造商，股票代码为NYSE:CTLT，是此次收购的核心。负责反垄断事务的欧盟委员会可以选择有条件地批准交易、无条件地批准交易，或者 ...

Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

周二，合同药品制造商Catalent（纽交所代码：CTLT）公布的第一季度收入未能达到华尔街预期。该公司目前正在被诺和诺德公司旗下的Novo Holdings收购，本季度出现了意外亏损。 Catalent以提供注射器和注射笔的无菌填充和包装服务而闻名，是诺和诺德公司（纽交所代码：NVO）Wegovy减肥药的主要供应商。今年2月，持有诺和诺德公司控股权的Novo Holdings启动了对Catale ...